HRP20230319T1 - Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka - Google Patents
Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka Download PDFInfo
- Publication number
- HRP20230319T1 HRP20230319T1 HRP20230319TT HRP20230319T HRP20230319T1 HR P20230319 T1 HRP20230319 T1 HR P20230319T1 HR P20230319T T HRP20230319T T HR P20230319TT HR P20230319 T HRP20230319 T HR P20230319T HR P20230319 T1 HRP20230319 T1 HR P20230319T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- acid
- ester
- salt
- Prior art date
Links
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 title claims 24
- 229940049636 dobesilic acid Drugs 0.000 title claims 24
- 230000000699 topical effect Effects 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 43
- 239000002253 acid Substances 0.000 claims 17
- 150000002148 esters Chemical class 0.000 claims 15
- 150000007513 acids Chemical class 0.000 claims 12
- 208000002780 macular degeneration Diseases 0.000 claims 9
- 230000007170 pathology Effects 0.000 claims 7
- 208000035719 Maculopathy Diseases 0.000 claims 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 5
- 230000002207 retinal effect Effects 0.000 claims 5
- 150000001342 alkaline earth metals Chemical class 0.000 claims 4
- 210000001328 optic nerve Anatomy 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 150000001340 alkali metals Chemical class 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 210000003161 choroid Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 208000033379 Chorioretinopathy Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 208000014769 Usher Syndromes Diseases 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 2
- 208000029517 toxic amblyopia Diseases 0.000 claims 2
- 210000004127 vitreous body Anatomy 0.000 claims 2
- 208000005598 Angioid Streaks Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims 1
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 claims 1
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 1
- 206010019899 Hereditary retinal dystrophy Diseases 0.000 claims 1
- 108700000201 Hyaloideoretinal degeneration of Wagner Proteins 0.000 claims 1
- 208000037060 Hyalosis asteroid Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 206010053678 Iridocorneal endothelial syndrome Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 1
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- 208000024080 Myopic macular degeneration Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 206010033712 Papilloedema Diseases 0.000 claims 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000021016 Retinal Arterial Macroaneurysm Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010064145 Retinal aneurysm Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 208000032458 Retinopathy solar Diseases 0.000 claims 1
- 208000027077 Stickler syndrome Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 1
- 208000034699 Vitreous floaters Diseases 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- 208000022482 Wagner disease Diseases 0.000 claims 1
- 208000029977 White Dot Syndromes Diseases 0.000 claims 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims 1
- -1 alkaline earth metal salt Chemical class 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000002165 neuroretinitis Diseases 0.000 claims 1
- 201000005799 nutritional optic neuropathy Diseases 0.000 claims 1
- 201000009015 preretinal fibrosis Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 201000001184 retinal microaneurysm Diseases 0.000 claims 1
- 230000004286 retinal pathology Effects 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 201000000824 solar retinopathy Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 208000000318 vitreous detachment Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u liječenju i/ili sprječavanju bolesti stražnjeg segmenta oka, pri čemu se liječenje sastoji u primjeni topikalne doze dobesilne kiseline i/ili farmaceutski prihvatljive soli, ili estera navedene kiseline ili soli, od 0,01 mg dnevno do 400 mg dnevno.
2. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, pri čemu se farmaceutski prihvatljivu sol bira između soli dobesilne kiseline s alkalnim metalom, soli dobesilne kiseline sa zemnoalkalnim metalom, soli dobesilne kiseline s aminom formule (II), te njihovih kombinacija:
[image]
,
pri čemu se R1, R2 i R3 neovisno bira između -(C1-C8)-alkilnih radikala ili H.
3. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2, gdje se navedenu farmaceutski prihvatljivu sol bira između soli dobesilne kiseline s alkalnim metalom, soli dobesilne kiseline sa zemnoalkalnim metalom, te njihovih kombinacija.
4. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, gdje je navedena sol dobesilne kiseline sa zemnoalkalnim metalom kalcijev dobesilat.
5. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2, gdje je navedena sol dobesilne kiseline s aminom formule (II), pri čemu su R1 i R2 jednaki i etilni su radikali.
6. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, pri čemu se bolest stražnjeg segmenta oka bira između patologija mrežnice i/ili žilnice, patologija staklastog tijela, patologija stražnjeg dijela bjeloočnice, patologija vidnog živca, te njihovih kombinacija.
7. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, pri čemu je bolest stražnjeg segmenta oka patologija mrežnice i/ili patologija žilnice, koju se bira između vaskulopatije mrežnice, makulopatije, nasljedne distrofije očne pozadine, idiopatske korioretinopatije, središnje serozne retinopatije, opće distrofije žilnice, te njihovih kombinacija.
8. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili njezine soli, namijenjen upotrebi u skladu s patentnim zahtjevom 7, pri čemu se vaskulopatiju mrežnice bira između dijabetične retinopatije, dijabetične papilopatije, nedijabetične retinopatije, sindroma očne ishemije, hipertenzivne retinopatije, talasemične retinopatije, Coatsovog sindroma, Ealesovog sindroma, radijacijske retinopatije, solarne retinopatije, Purtscherove retinopatije, polipoidne vaskulopatije žilnice (PCV), makroaneurizme mrežnice, mikroaneurizme mrežnice, leukemične retinopatije, ishemije mrežnice, kroničnih poremećaja mrežnice, te njihovih kombinacija.
9. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s patentnim zahtjevom 7, pri čemu se makulopatiju bira između staračke degeneracije makule (ARMD), hemorhagijskog ARMD, angiomatozne proliferacije mrežnice, polipoidne vaskulopatije žilnice, Doyneove saćaste distrofije mrežnice, makularne rupe pune debljine, makularne epiretinalne membrane, teleangiektazije makule, celofanske makulopatije ili ispupčenja makule, miopijske makulopatije, eksudativne makulopatije nakon venozne tromboze mrežnice, akutne neuroretinopatije makule, cistoida makule, edema makule, angioidnih tračaka mrežnice, nabora žilnice, hipotonične makulopatije i njihovih kombinacija; i pri čemu se nasljednu distrofiju očne pozadine bira iz skupine koju čine pigmentozni retinitis; atipični pigmentozni retinitis, uključujući, no bez ograničavanja na Usherov sindrom, retinitis punktata albikans, Leberova prirođena amauroza, distrofija čunjića, distrofija štapića, Biettijeva kristalna korneoretinalna distrofija, mladenačka distrofija makule, svi tipovi distrofije makule, Stargardtova bolest ili Fundus flavimaculatus, Usherov sindrom i njihove kombinacije.
10. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, pri čemu je bolest stražnjeg segmenta oka patologija staklastog tijela, koju se bira iz skupine koju čine submakularno krvarenje i krvarenje u staklastom tijelu, asteroidna hijaloza, odljuštenje staklastog tijela, očne mušice ili miodezopsija, nasljedne vitreoretinopatije, Sticklerov sindrom ili Wagnerov sindrom, te njihove kombinacije.
11. Dobesilna kiselina i/ili farmaceutski prihvatljiva sol, ili ester bilo koje od kiseline ili soli, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, pri čemu je bolest stražnjeg segmenta oka patologija vidnog živca, koju se bira iz skupine koju čine atrofija vidnog živca, upala vidnog živca, neuroretinitis, ishemična neuropatija, nasljedna neuropatija vidnog živca, toksična ambliopija ili nutritivna neuropatija vidnog živca, očna hipertenzija, primarni glaukom, sekundarni glaukom, iridokornealni endotelni sindrom povezan s glaukomom, druze glave vidnog živca ili druze optičkog diska, papiloedem i njihove kombinacije.
12. Farmaceutski topikalni očni pripravak, namijenjen upotrebi u liječenju i/ili sprječavanju bolesti stražnjeg segmenta oka, koji sadrži terapijski djelotvornu količinu dobesilne kiseline i/ili farmaceutski prihvatljive soli, ili estera bilo koje od kiseline ili soli, zajedno s jednim ili više farmaceutski prihvatljivih topikalnih pomoćnih sredstava i/ili nosača; pri čemu se liječenje sastoji u primjeni topikalne doze dobesilne kiseline i/ili farmaceutski prihvatljive soli, ili njezinog estera, od 0,01 mg dnevno do 400 mg dnevno.
13. Farmaceutski topikalni očni pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 12, koji sadrži dobesilnu kiselinu i/ili farmaceutski prihvatljivu sol, ili ester bilo koje od kiseline ili soli, u postocima prema težini kroz volumen, od 0,02% do 20% tež./vol.
14. Farmaceutski topikalni očni pripravak, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 12-13, pri čemu se farmaceutski prihvatljivu sol bira između soli dobesilne kiseline s alkalnim metalom, soli dobesilne kiseline sa zemnoalkalnim metalom, soli dobesilne kiseline s aminom formule (II), te njihovih kombinacija:
[image]
,
pri čemu se R1, R2 i R3 neovisno bira između -(C1-C8)-alkilnih radikala ili H.
15. Farmaceutski topikalni očni pripravak, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 12-14, pri čemu je farmaceutski prihvatljiva sol sol dobesilne kiseline sa zemnoalkalnim metalom, kalcijev dobesilat.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382832 | 2017-12-04 | ||
| EP18811023.3A EP3720428B1 (en) | 2017-12-04 | 2018-11-29 | Ophthalmic topical composition comprisng dobesilic acid for treating diseases of the posterior segment of the eye |
| PCT/EP2018/082999 WO2019110416A1 (en) | 2017-12-04 | 2018-11-29 | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230319T1 true HRP20230319T1 (hr) | 2023-05-12 |
Family
ID=60673756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230319TT HRP20230319T1 (hr) | 2017-12-04 | 2018-11-29 | Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20200390729A1 (hr) |
| EP (1) | EP3720428B1 (hr) |
| JP (1) | JP2021505554A (hr) |
| KR (1) | KR20200096569A (hr) |
| CN (1) | CN111542316A (hr) |
| AU (1) | AU2018378981A1 (hr) |
| BR (1) | BR112020011160A2 (hr) |
| CA (1) | CA3083835A1 (hr) |
| CL (1) | CL2020001426A1 (hr) |
| DK (1) | DK3720428T3 (hr) |
| ES (1) | ES2941036T3 (hr) |
| FI (1) | FI3720428T3 (hr) |
| HR (1) | HRP20230319T1 (hr) |
| HU (1) | HUE061852T2 (hr) |
| MA (1) | MA50991B1 (hr) |
| MX (1) | MX2020005809A (hr) |
| PH (1) | PH12020550722A1 (hr) |
| PL (1) | PL3720428T3 (hr) |
| PT (1) | PT3720428T (hr) |
| SG (1) | SG11202004940VA (hr) |
| SI (1) | SI3720428T1 (hr) |
| WO (1) | WO2019110416A1 (hr) |
| ZA (1) | ZA202003944B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117257963A (zh) * | 2023-11-02 | 2023-12-22 | 广州准优生物科技有限公司 | 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途 |
| CN117643573B (zh) * | 2024-01-29 | 2024-05-03 | 天津医科大学眼科医院 | 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US9198886B2 (en) * | 2006-08-16 | 2015-12-01 | Pedro Cuevas Sánchez | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| CA2855223A1 (en) * | 2011-11-30 | 2013-06-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
| EP2777699B1 (en) | 2012-02-02 | 2017-03-29 | Invesfovea S.L. | Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration |
| PL2822964T3 (pl) * | 2012-03-05 | 2019-05-31 | Univ Wayne State | Identyfikacja mutacji opsyny kanałowej 2 (chop2) i sposoby stosowania |
| AU2013254690B2 (en) * | 2012-04-24 | 2017-12-07 | Thrombogenics N.V. | Anti-PDGF-C antibodies |
| EP2875811A1 (en) | 2013-11-26 | 2015-05-27 | Luis Antonio Outeirino Miguez | Use of dobesilate for treating ocular haemorrhages |
-
2018
- 2018-11-29 SI SI201830869T patent/SI3720428T1/sl unknown
- 2018-11-29 ES ES18811023T patent/ES2941036T3/es active Active
- 2018-11-29 CA CA3083835A patent/CA3083835A1/en active Pending
- 2018-11-29 MA MA50991A patent/MA50991B1/fr unknown
- 2018-11-29 HU HUE18811023A patent/HUE061852T2/hu unknown
- 2018-11-29 SG SG11202004940VA patent/SG11202004940VA/en unknown
- 2018-11-29 KR KR1020207018983A patent/KR20200096569A/ko not_active Application Discontinuation
- 2018-11-29 DK DK18811023.3T patent/DK3720428T3/da active
- 2018-11-29 PL PL18811023.3T patent/PL3720428T3/pl unknown
- 2018-11-29 US US16/770,027 patent/US20200390729A1/en active Pending
- 2018-11-29 AU AU2018378981A patent/AU2018378981A1/en active Pending
- 2018-11-29 FI FIEP18811023.3T patent/FI3720428T3/fi active
- 2018-11-29 EP EP18811023.3A patent/EP3720428B1/en active Active
- 2018-11-29 WO PCT/EP2018/082999 patent/WO2019110416A1/en unknown
- 2018-11-29 MX MX2020005809A patent/MX2020005809A/es unknown
- 2018-11-29 CN CN201880082202.1A patent/CN111542316A/zh active Pending
- 2018-11-29 HR HRP20230319TT patent/HRP20230319T1/hr unknown
- 2018-11-29 PT PT188110233T patent/PT3720428T/pt unknown
- 2018-11-29 JP JP2020529733A patent/JP2021505554A/ja active Pending
- 2018-11-29 BR BR112020011160-0A patent/BR112020011160A2/pt unknown
-
2020
- 2020-05-27 PH PH12020550722A patent/PH12020550722A1/en unknown
- 2020-05-28 CL CL2020001426A patent/CL2020001426A1/es unknown
- 2020-06-29 ZA ZA2020/03944A patent/ZA202003944B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020550722A1 (en) | 2021-02-15 |
| ZA202003944B (en) | 2022-12-21 |
| EP3720428A1 (en) | 2020-10-14 |
| US20200390729A1 (en) | 2020-12-17 |
| PL3720428T3 (pl) | 2023-05-08 |
| BR112020011160A2 (pt) | 2020-11-17 |
| CN111542316A (zh) | 2020-08-14 |
| MA50991A (fr) | 2020-10-14 |
| DK3720428T3 (da) | 2023-03-20 |
| FI3720428T3 (fi) | 2023-03-30 |
| WO2019110416A1 (en) | 2019-06-13 |
| MA50991B1 (fr) | 2023-03-31 |
| MX2020005809A (es) | 2020-08-20 |
| HUE061852T2 (hu) | 2023-08-28 |
| AU2018378981A1 (en) | 2020-07-16 |
| ES2941036T3 (es) | 2023-05-16 |
| JP2021505554A (ja) | 2021-02-18 |
| KR20200096569A (ko) | 2020-08-12 |
| CA3083835A1 (en) | 2019-06-13 |
| SG11202004940VA (en) | 2020-06-29 |
| SI3720428T1 (sl) | 2023-05-31 |
| CL2020001426A1 (es) | 2020-11-06 |
| PT3720428T (pt) | 2023-04-03 |
| EP3720428B1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5421272B2 (ja) | 眼病治療のための組成物及び方法 | |
| CA2585691C (en) | Enhanced bimatoprost ophthalmic solution | |
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| DK2403493T3 (en) | Non-steroidal anti-inflammatory ophthalmic compositions | |
| JP2014527407A5 (hr) | ||
| HRP20230319T1 (hr) | Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka | |
| JP2013526572A5 (hr) | ||
| IL290069B2 (en) | Methods for treating eye conditions | |
| EP2794008A1 (en) | Combination anti-inflammatory ophthalmic compositions | |
| JP2011037891A5 (hr) | ||
| CA2807081C (en) | Preservative free bimatoprost and timolol solutions | |
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| AU2005260090A1 (en) | Lubricant for the ocular surface | |
| US20150099807A1 (en) | Preservative free bimatoprost solutions | |
| JP2021505554A5 (hr) | ||
| JP2011512362A (ja) | 眼科応用のためのフルオロキノロン誘導体 | |
| RU2018102746A (ru) | Офтальмологическая фармацевтическая композиция | |
| JP2012505928A5 (hr) | ||
| Hajare et al. | A rational approach to ocular drug delivery system: a overview | |
| WO2009067317A2 (en) | Use of levocabastine for modulating generation of pro- inflammatory cytokines | |
| JP2009517375A (ja) | 眼の疾患の治療 | |
| EP2558100A1 (en) | Compositions and methods for treating visual disorders | |
| RU2019118904A (ru) | Распределение в глазу и фармакокинетика композиций лифитеграста | |
| JPWO2021021646A5 (hr) | ||
| IL303513A (en) | Compounds for the treatment of eye diseases |